Tag Archives | molecular diagnostics

Slower Growth in Diagnostics Stocks Except for NexGen Sequencing and Molecular

New technologies in diagnostics and tools are driving growth: NexGen sequencing, molecular and “point-of-care” testing platforms and veterinary testing. M&A and consolidation should continue. The sector is a laggard due to slowing  sales and earnings growth vs forecasts. Rayno Clinical Diagnostics Portfolio Update We initiated coverage of Clinical Diagnostic and Life Science Tools stocks in […]

Continue Reading 0

Rayno Life Sciences DX and Tools Update: 2015 Q1 Winners ALR,FMI,HOLX

Diagnostic Stocks rally with NASDAQ and Small Caps –IWM Up 1.66% Life Science Tools and Diagnostics stocks are a tad off their one year highs hit by dollar strength and disappointing revenue growth in some cases. Sequencing stocks were big winners but sold off after the JPMorgan Conference. Nonetheless the sector is attractive longer term […]

Continue Reading 0

Rayno Dx and Tools: Update EXAS

Valuation Does Matter If Revenue Growth Slows Last week we posted a YTD summary of our diagnostics and tools focus stocks. Three stocks that are up over one year but have been weak in 2015. We said that revenue guidance and technicals will be important for: Exact Sciences (EXAS), Genomic Health (GHDX) and Neogen (NEOG). […]

Continue Reading 0

Rayno Dx and Tools: 2015 Q1 Mid Quarter Update-FMI, CSII, HOLX, ALR

Bullish Trend Continues for Mid-Cap Growth Stocks The Life Science Tools and Clinical Diagnostics sector kept pace with major life science ETF performance. Major  ETFs (FBT,IBB,XBI) are up about 10% YTD and our top performers are up over 10%. We will provide an update of our  Clinical Diagnostics portfolio after all earnings reports are in. […]

Continue Reading 0

Rayno Dx and Tools Portfolio: CSII HOLX ILMN TMO Stellar Performers

Solid  earnings reports-All of Our Picks Are Strong Holds But Strong Dollar a Factor in 2105 Cardiovascular Systems (CSII) Stock Soars 15% On Strong Revenues Interventional treatments for cardiovascular disease Q2 Revenues soared 38% to $44.7M compared to previous fiscal Q2 2014. Fiscal Q2 2105 loss was $5.3M or (0.17) per share. Hologic (HOLX) Beats […]

Continue Reading 0